2-(2-氨基噻唑-4-基)丁酸乙酯 | 412311-88-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(2-氨基噻唑-4-基)丁酸乙酯
• 英文名称: ethyl 2-(2-aminothiazol-4-yl)butanoate
• 英文别名: Ethyl 2-(2-aminothiazol-4-yl)butanoate；ethyl 2-(2-amino-1,3-thiazol-4-yl)butanoate
• CAS: 412311-88-7
• 化学式: C₉H₁₄N₂O₂S
• 分子量: 214.288
• InChiKey: ZKPUWDUVLLOOQK-UHFFFAOYSA-N

物化性质

• 熔点：
  104-105 °C
• 沸点：
  330.3±17.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  93.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(2-氨基噻唑-4-基)丁酸乙酯 在 sodium hydroxide 作用下， 生成 4-丙基噻唑-2-胺
  参考文献：
  名称：

  Preparation of 2-Amino-4-alkylthiazoles from Esters of Substituted 2-Aminothiazyl-4-acetic Acids

  摘要：

  DOI：

  10.1021/ja01856a024
• 作为产物：
  描述：

  2-乙基乙酰乙酸乙酯 在 溴 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 0.5h， 生成 2-(2-氨基噻唑-4-基)丁酸乙酯
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of Conformationally Restricted Acetanilides as Potent and Selective β₃Adrenergic Receptor Agonists for the Treatment of Overactive Bladder

  摘要：

  A series of conformationally restricted acetanilides were synthesized and evaluated as beta(3)-adrenergic receptor agonists (beta(3)-AR) for the treatment of overactive bladder (OAB). Optimization studies identified a five-membered ring as the preferred conformational lock of the acetanilide. Further optimization of both the aromatic and thiazole regions led to compounds such as 19 and 29, which have a good balance of potency and selectivity. These compounds have significantly reduced intrinsic clearance compared to our initial series of pyridylethanolamine beta(3)-AR agonists and thus have improved unbound drug exposures. Both analogues demonstrated dose dependent beta(3)-AR mediated responses in a rat bladder hyperactivity model.

  DOI：

  10.1021/jm4017224

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：STEP PHARMA S A S

  公开号：WO2019106156A1

  公开（公告）日：2019-06-06

  Compounds of formula (I): (I) and related aspects.

  式(I)的化合物及相关方面。
• [EN] HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS<br/>[FR] HETEROARYL-UREES ET LEUR UTILISATION EN TANT QU'ACTIVATEURS DE GLUCOKINASE
  申请人：NOVO NORDISK AS

  公开号：WO2005066145A1

  公开（公告）日：2005-07-21

  This invention relates to compounds that are of formula (I) wherein A is heteroaryl and R1 and R2 are both cyclic residues, that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial .

  这项发明涉及具有以下结构的化合物（I），其中A是杂环烷基，R1和R2都是环状残基，这些化合物是葡萄糖激酶的激活剂，因此可能对管理、治疗、控制或辅助治疗需要增加葡萄糖激酶活性的疾病有益。
• Heteroaryl-Ureas and Their Use as Glucokinase Activators
  申请人：Murray Anthony

  公开号：US20090216013A1

  公开（公告）日：2009-08-27

  This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

  本发明涉及公式（I）的化合物，其为葡萄糖激酶激活剂，因此可能对增加葡萄糖激酶活性有益的疾病的管理、治疗、控制或辅助治疗有用。
• Heteroaryl-ureas and their use as glucokinase activators
  申请人：Murray Anthony

  公开号：US20070054897A1

  公开（公告）日：2007-03-08

  This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

  本发明涉及式（I）的化合物，它们是葡萄糖激酶的激活剂，因此可能对增加葡萄糖激酶活性有益的疾病的管理、治疗、控制或辅助治疗有用。
• HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS
  申请人：Murray Anthony

  公开号：US20110060019A1

  公开（公告）日：2011-03-10

  This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

  本发明涉及式（I）化合物，其为葡萄糖激酶的激活剂，因此可能有助于治疗、控制或辅助治疗增加葡萄糖激酶活性有益的疾病。